
The allotment status for the RFBL Flexi Pack ₹35.33 crore IPO is expected to be declared today, May 15, 2026. Investors will be able to verify their IPO allotment through official channels, including the NSE website and the registrar's website, KFin Technologies Limited.
Issue Type: Book Building IPO
Total Issue size: Up to 70.65 lakh equity Shares
Fresh Issue: Up to 70.65 lakh equity Shares
Price Band: ₹47 to ₹50 per share
Face Value: ₹ 10 each
Lot Size: 3,000 shares
Minimum Investment (Retail Investor): ₹100 (6,000 shares)
Book Running Lead Managers: Grow House Wealth Management Private Limited
Registrar: KFin Technologies Limited
Listing: NSE SME
[May 14, 2026, 07:00 PM]
|
Category |
Subscription (Times) |
|
Qualified Institutional Buyers (QIBs) |
124.39 |
|
Non-Institutional Investors (NIIs) |
24.12 |
|
Retail Investors |
11.36 |
|
Total |
21.48 |
According to reports, the Grey Market Premium (GMP) of RFBL Flexi Pack is ₹4 per share today.
The Company will utilise the net proceeds from the Fresh Issue towards the following purposes:
Check out newly listed IPOs on BSE and NSE.
Operating in the B2B market, RFBL Flexi Pack Limited delivers customised, high-quality packaging solutions to a diverse client base. The company focuses on producing and distributing multilayered flexible packaging solutions, such as plastic film rolls and pouches, designed to meet various industrial requirements.
To ensure moisture resistance, strength, and effective barrier protection, the company utilises high-grade materials including Cast Polypropylene (CPP), Cast Polyethene (CPE), and BOPP films, along with specialised adhesives and inks.
The end products find extensive usage in the packaging of goods in various industries, some of which are:
As of the period ended November 30, 2025, the company reported revenue from operations of ₹6,966.49 lakh. During the same period, Profit after Tax (PAT) was ₹383.72 lakh with EBITDA of ₹595.7 lakh.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.